4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow Rhinitis, Allergic: new trials by email Literature Review of Rhinitis, Allergic trials Research Report on Rhinitis, Allergic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber Sublingual allergy immunological tablet, Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Terminated | ALK-Abelló A/S | 80 | 2019-11-04 | 2022-06-30 |
| Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy allergen extract tablet, Placebo tablet - Immunologic Desensitization | Phase 3 | Terminated | Virginia Commonwealth University | 58 | 2016-06-01 | 2022-03-18 |
| Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients Fluticasone propionate, Flonase®, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Terminated | Teva Pharmaceuticals USA | 1474 | 2014-03-01 | 2023-06-08 |
Rhinitis, Allergic, Seasonal (2) · Conjunctivitis, Allergic (1) · Dust Mite Allergy (1) · Hypersensitivity (1) · Rhinitis, Allergic, Perennial (1)
Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4) · Rhinitis (4) · Hypersensitivity (3) · Conjunctival Diseases (1) · Conjunctivitis (1) · Eye Diseases (1)
Allergens (1) · Fluticasone (1)
ALK-Abelló A/S (1) · Inmunotek S.L. (1) · Teva Pharmaceuticals USA (1) · Virginia Commonwealth University (1)
United States (2) · Austria (1) · China (1) · Spain (1)
Ana Isabel Tabar Purroy, MD; PhD (1) · Lawrence B Schwartz, M.D.,Ph.D. (1) · Luo Zhang, Prof. (1)
2018 (1)